Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Hutchison MediPharma Starts Clinical Trial on Fourth Cancer Drug

publication date: Nov 2, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Hutchison MediPharma, the drug discovery arm of China MediTech, has begun a Phase I clinical trial of Theliatinib (HMPL-309) in patients with non-small cell lung cancer. The drug is a small molecule inhibitor of the epidermal growth factor receptor tyrosine kinase. Unlike most EGFR inhibitors, Theliatinib has shown efficacy against NSCLC that does not display EGFR-enabling mutations in pre-clinical testing, according to Chi-Med. More details....

Stock Symbol: (AIM: HCM)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
ChinaBio Leadership Retreat 2014
Suzhou, China
October 23-24, 2014
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors